Rossi L - Search Results

1

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Rossi L, McCartney A, Risi E, Malorni L, Biganzoli L, Di Leo A. Rossi L, et al. Ther Adv Med Oncol. 2018 Dec 10;10:1758835918815591. doi: 10.1177/1758835918815591. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30574210 Free PMC article.

2

Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.

Rossi L, Biagioni C, McCartney A, Moretti E, Pestrin M, Sanna G, Risi E, Malorni L, DI Leo A, Biganzoli L. Rossi L, et al. Anticancer Res. 2018 Aug;38(8):4839-4845. doi: 10.21873/anticanres.12795. Anticancer Res. 2018. PMID: 30061257

3

The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review.

Rossi L, McCartney A, De Santo I, Risi E, Moretti E, Malorni L, Biganzoli L, Di Leo A. Rossi L, et al. Cancer Treat Rev. 2019 Mar;74:29-34. doi: 10.1016/j.ctrv.2019.01.007. Epub 2019 Jan 25. Cancer Treat Rev. 2019. PMID: 30708267 Review.

4

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C, Arpino G, Bernardo A, Martignetti A, Risi E, Pestrin M, Boni L, Benelli M, Biganzoli L, Di Leo A, Malorni L. Rossi L, et al. Breast Cancer Res. 2019 May 29;21(1):71. doi: 10.1186/s13058-019-1149-5. Breast Cancer Res. 2019. PMID: 31142370 Free PMC article.

5

Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution.

Barchiesi G, McCartney A, Biagioni C, Siclari O, Rossi L, Pestrin M, Di Leo A, Biganzoli L. Barchiesi G, et al. Among authors: rossi l. Breast J. 2019 Nov;25(6):1225-1229. doi: 10.1111/tbj.13437. Epub 2019 Jul 16. Breast J. 2019. PMID: 31310384

6

Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.

Rossi L, McCartney A, Risi E, De Santo I, Migliaccio I, Malorni L, Biganzoli L, Di Leo A. Rossi L, et al. Clin Breast Cancer. 2019 Dec;19(6):392-398. doi: 10.1016/j.clbc.2019.05.019. Epub 2019 Jun 11. Clin Breast Cancer. 2019. PMID: 31358432 Review.

7

Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification.

McCartney A, Vignoli A, Tenori L, Fornier M, Rossi L, Risi E, Luchinat C, Biganzoli L, Di Leo A. McCartney A, et al. Among authors: rossi l. NPJ Breast Cancer. 2019 Aug 29;5:26. doi: 10.1038/s41523-019-0123-9. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31482106 Free PMC article.

8

Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: a multicenter analysis.

Gasparri ML, Albasini S, Truffi M, Favilla K, Tagliaferri B, Piccotti F, Bossi D, Armatura G, Calcinotto A, Chiappa C, Combi F, Curcio A, Della Valle A, Ferrari G, Folli S, Ghilli M, Listorti C, Mancini S, Marinello P, Mele S, Pertusati A, Roncella M, Rossi L, Rovera F, Segattini S, Sgarella A, Tognali D, Corsi F. Gasparri ML, et al. Among authors: rossi l. Ther Adv Med Oncol. 2023 Sep 15;15:17588359231193732. doi: 10.1177/17588359231193732. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37720495 Free PMC article.

9

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.

Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. Partridge AH, et al. N Engl J Med. 2023 May 4;388(18):1645-1656. doi: 10.1056/NEJMoa2212856. N Engl J Med. 2023. PMID: 37133584 Free PMC article. Clinical Trial.

10

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies.

Nerone M, Rossi L, Condorelli R, Ratti V, Conforti F, Palazzo A, Graffeo R. Nerone M, et al. Among authors: rossi l. Cancers (Basel). 2023 Jun 23;15(13):3305. doi: 10.3390/cancers15133305. Cancers (Basel). 2023. PMID: 37444415 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,714 results

Search Page